A Phase II Study of Everolimus (RAD001) for Children with Neurofibromatosis Type I and Chemotherapy-Refractory Radiographic Progressive Low-Grade

Grant

Awarded By

Total Award Amount

  • 84503.00

    • Direct Costs

  • 76821.00

    • Sponsor Award Id

    • Contributor

  • Bruce Korf M.D., Ph.D.   Principal Investigator  
  • Gary Cutter   Investigator